SMT201800504T1 - Composti e loro metodi di utilizzo - Google Patents

Composti e loro metodi di utilizzo

Info

Publication number
SMT201800504T1
SMT201800504T1 SM20180504T SMT201800504T SMT201800504T1 SM T201800504 T1 SMT201800504 T1 SM T201800504T1 SM 20180504 T SM20180504 T SM 20180504T SM T201800504 T SMT201800504 T SM T201800504T SM T201800504 T1 SMT201800504 T1 SM T201800504T1
Authority
SM
San Marino
Prior art keywords
compounds
methods
Prior art date
Application number
SM20180504T
Other languages
English (en)
Italian (it)
Inventor
Janeta Popovici-Muller
Francesco G Salituro
Jeffrey O Saunders
Jeremy M Travins
Rene M Lemieux
Yongsheng Chen
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of SMT201800504T1 publication Critical patent/SMT201800504T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SM20180504T 2012-11-22 2013-11-21 Composti e loro metodi di utilizzo SMT201800504T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2012/085023 WO2014079011A1 (en) 2012-11-22 2012-11-22 Heterocyclic compounds for inhibiting glutaminase and their methods of use
PCT/CN2013/000294 WO2014079136A1 (en) 2012-11-22 2013-03-15 Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof
PCT/CN2013/001428 WO2014079150A1 (en) 2012-11-22 2013-11-21 Compounds and their methods of use
EP13857585.7A EP2922850B1 (en) 2012-11-22 2013-11-21 Compounds and their methods of use

Publications (1)

Publication Number Publication Date
SMT201800504T1 true SMT201800504T1 (it) 2018-11-09

Family

ID=50775393

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20180504T SMT201800504T1 (it) 2012-11-22 2013-11-21 Composti e loro metodi di utilizzo

Country Status (36)

Country Link
US (3) US10087172B2 (enExample)
EP (2) EP2922850B1 (enExample)
JP (2) JP6333277B2 (enExample)
KR (1) KR20150085079A (enExample)
CN (2) CN104936954B (enExample)
AR (1) AR093598A1 (enExample)
AU (2) AU2013347771B2 (enExample)
BR (1) BR112015011830A2 (enExample)
CA (1) CA2893510C (enExample)
CL (1) CL2015001392A1 (enExample)
CR (1) CR20150316A (enExample)
CY (1) CY1120581T1 (enExample)
DK (1) DK2922850T3 (enExample)
EA (2) EA201890754A1 (enExample)
EC (1) ECSP15026557A (enExample)
ES (1) ES2690390T3 (enExample)
HR (1) HRP20181628T1 (enExample)
HU (1) HUE040111T2 (enExample)
IL (1) IL238958B (enExample)
LT (1) LT2922850T (enExample)
MX (1) MX367389B (enExample)
MY (1) MY177344A (enExample)
NZ (1) NZ708382A (enExample)
PE (1) PE20151072A1 (enExample)
PH (2) PH12015501150B1 (enExample)
PL (1) PL2922850T3 (enExample)
PT (1) PT2922850T (enExample)
RS (1) RS57859B1 (enExample)
SA (1) SA515360469B1 (enExample)
SG (2) SG10201609940RA (enExample)
SI (1) SI2922850T1 (enExample)
SM (1) SMT201800504T1 (enExample)
TR (1) TR201812360T4 (enExample)
TW (2) TWI629268B (enExample)
UA (1) UA117360C2 (enExample)
WO (3) WO2014079011A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
HUE056078T2 (hu) 2012-11-16 2022-01-28 Calithera Biosciences Inc Heterociklusos glutamináz inhibitorok
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
HK1220640A1 (zh) * 2012-12-03 2017-05-12 Calithera Biosciences, Inc. 用谷氨醯胺酶的杂环抑制剂治疗癌症
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
TWI662030B (zh) 2013-01-15 2019-06-11 英塞特控股公司 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
EA201691896A1 (ru) 2014-03-21 2017-01-30 Аджиос Фармасьютикалз, Инк. Соединения и способы их применения
HRP20192056T1 (hr) * 2014-04-30 2020-02-21 Pfizer Inc. Derivati diheterocikla vezani na cikloalkil
GB201409624D0 (en) * 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
SG11201610333VA (en) * 2014-06-13 2017-01-27 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors
PL3164394T3 (pl) 2014-07-03 2020-09-07 Board Of Regents, The University Of Texas System Inhibitory GLS1 do leczenia chorób
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
JP6889101B2 (ja) 2014-08-07 2021-06-18 キャリセラ バイオサイエンシーズ, インコーポレイテッド グルタミナーゼ阻害剤の結晶形態
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
JP6768693B2 (ja) * 2015-03-30 2020-10-14 キャリセラ バイオサイエンシーズ, インコーポレイテッド グルタミナーゼ阻害剤を投与する方法
BR112017021312A2 (pt) 2015-04-06 2018-06-26 Calithera Biosciences Inc tratamento de câncer de pulmão com inibidores de glutaminase
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
CN107921044B (zh) 2015-06-30 2022-01-21 德州大学系统董事会 用于治疗疾病的gls1抑制剂
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
US10556884B2 (en) 2015-09-28 2020-02-11 Syngenta Participations Ag Pesticidally active heterocyclic derivatives with sulphur containing substituents
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
SG11201802830QA (en) 2015-10-05 2018-05-30 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors and immuno-oncology agents
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN109503570B (zh) * 2015-12-18 2020-08-25 诺言医药科技(上海)有限公司 一种含有索拉非尼的药物组合物及其应用
KR102777513B1 (ko) 2015-12-22 2025-03-06 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 (r)-1-(4-(6-(2-(4-(3,3-디플루오로시클로부톡시)-6-메틸피리딘-2-일)아세트아미도)피리다진-3-일)-2-플루오로부틸)-n-메틸-1h-1,2,3-트리아졸-4-카르복사미드의 염 형태 및 다형체
WO2018039544A1 (en) * 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
WO2018039441A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US10722487B2 (en) 2017-10-18 2020-07-28 Board Of Regents, The University Of Texas System Glutaminase inhibitor therapy
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University COMBINATION THERAPY FOR A PI3K-ASSOCIATED DISEASE OR DISORDER
WO2020096916A2 (en) 2018-11-08 2020-05-14 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
US12628858B2 (en) 2019-03-21 2026-05-19 Cornell University Therapy for colorectal and small intestine cancers
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
KR20230037640A (ko) 2020-07-10 2023-03-16 구알티에로 크로촐리 수렴형 타원 트랙에 볼 또는 롤러를 구비하는 차동장치
CN112898200A (zh) * 2021-01-20 2021-06-04 都创(上海)医药科技股份有限公司 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
SU1761672A1 (ru) * 1990-05-22 1992-09-15 Белгородский технологический институт строительных материалов им.И.А.Гришманова Способ получени тонкодисперсного мела
JPH08508270A (ja) 1993-03-29 1996-09-03 ビーエーエスエフ アクチエンゲゼルシャフト マルチ・ドラッグ耐性のモジュレーターとしての1−アミノ−3−フェノキシ−プロパン誘導体
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
AU768751B2 (en) * 1998-06-18 2004-01-08 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
AU2001249064A1 (en) 2000-02-22 2001-09-03 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
ATE261126T1 (de) 2002-08-01 2004-03-15 Mtm Lab Ag Verfahren für lösung-basierte diagnose
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
WO2006101925A2 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2008048967A1 (en) 2006-10-16 2008-04-24 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
BRPI0817393A2 (pt) 2007-11-19 2015-03-31 Genentech Inc Anticorpo monoclonal, polipetídeo solúvel isolado, método de inibição do progresso de tumores, método de inibição de emt em células e método de determinação se um tumor reagirá a um antagonista de b2 ou um antagonista de notch
US7951549B2 (en) 2008-03-07 2011-05-31 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
US10532034B2 (en) 2009-03-25 2020-01-14 Cornell University Inhibition of glutaminase C
WO2010120966A1 (en) 2009-04-17 2010-10-21 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20130109643A1 (en) * 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
AU2011270968C1 (en) 2010-06-23 2017-01-19 University Of Louisville Research Foundation, Inc. Methods for detecting cancer
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN108785305B (zh) * 2011-11-21 2021-10-29 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
US20150037354A1 (en) 2012-03-15 2015-02-05 The Resesrch Foundation for The State University of New York Combination therapies including inhibitors of the extracellular domain of e-cadherin
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
WO2014138391A1 (en) 2013-03-06 2014-09-12 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
EA201691896A1 (ru) 2014-03-21 2017-01-30 Аджиос Фармасьютикалз, Инк. Соединения и способы их применения

Also Published As

Publication number Publication date
RS57859B1 (sr) 2018-12-31
CN104936954A (zh) 2015-09-23
EA201590987A1 (ru) 2015-12-30
SI2922850T1 (sl) 2018-10-30
ES2690390T3 (es) 2018-11-20
IL238958B (en) 2019-09-26
HK1214593A1 (en) 2016-07-29
IL238958A0 (en) 2015-07-30
TW201427963A (zh) 2014-07-16
CA2893510A1 (en) 2014-05-30
CL2015001392A1 (es) 2016-04-22
MX367389B (es) 2019-08-19
SG10201609940RA (en) 2016-12-29
CA2893510C (en) 2021-01-19
EA201890754A1 (ru) 2018-08-31
PH12015501150A1 (en) 2015-08-17
US10689375B2 (en) 2020-06-23
SG11201504049VA (en) 2015-07-30
US20140142081A1 (en) 2014-05-22
WO2014079150A1 (en) 2014-05-30
TWI629268B (zh) 2018-07-11
HRP20181628T1 (hr) 2018-12-14
JP2018150316A (ja) 2018-09-27
MY177344A (en) 2020-09-13
HUE040111T2 (hu) 2019-02-28
PH12015501150B1 (en) 2018-05-04
AU2013347771B2 (en) 2018-02-01
EP2922850B1 (en) 2018-07-18
PL2922850T3 (pl) 2018-12-31
US10087172B2 (en) 2018-10-02
US9029531B2 (en) 2015-05-12
PT2922850T (pt) 2018-10-15
AR093598A1 (es) 2015-06-10
SA515360469B1 (ar) 2017-07-11
AU2018202954A1 (en) 2018-05-17
DK2922850T3 (en) 2018-10-08
CR20150316A (es) 2015-08-28
LT2922850T (lt) 2018-09-10
PE20151072A1 (es) 2015-08-26
EA030646B1 (ru) 2018-09-28
TR201812360T4 (tr) 2018-09-21
NZ708382A (en) 2020-04-24
JP6333277B2 (ja) 2018-05-30
WO2014079136A1 (en) 2014-05-30
US20150291576A1 (en) 2015-10-15
CN104936954B (zh) 2018-08-14
PH12017502141A1 (en) 2019-02-27
UA117360C2 (uk) 2018-07-25
AU2013347771A1 (en) 2015-06-11
BR112015011830A2 (pt) 2017-07-11
ECSP15026557A (es) 2016-01-29
EP3456719A1 (en) 2019-03-20
CY1120581T1 (el) 2019-07-10
JP2016500082A (ja) 2016-01-07
KR20150085079A (ko) 2015-07-22
MX2015006493A (es) 2015-08-05
WO2014079011A1 (en) 2014-05-30
CN108727307A (zh) 2018-11-02
EP2922850A1 (en) 2015-09-30
US20190084976A1 (en) 2019-03-21
EP2922850A4 (en) 2016-05-18
TW201906825A (zh) 2019-02-16

Similar Documents

Publication Publication Date Title
SG11201504049VA (en) Compounds and their methods of use
ZA201405248B (en) Anesthetic compounds and related methods of use
ZA201502503B (en) Hppd variants and methods of use
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
IL233476B (en) Carbamate compounds and methods for their production and use
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
SG11201504022RA (en) Glutamase inhibitors and method of use
SG11201502757QA (en) Anti-c16orf54 antibodies and methods of use thereof
EP2709999A4 (en) CHINAZOLIN-7-ETHER COMPOUNDS AND ITS APPLICATION
ZA201406082B (en) Use of ccr3-inhibitors
ZA201408856B (en) Heteroaryl compounds and methods of use thereof
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
AU2012900650A0 (en) Compounds and methods of their use
AU2012900651A0 (en) Compounds and methods of their use
GB201213726D0 (en) Novel compounds and their use
AU2012903090A0 (en) Compounds and methods of their use - IV
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment